Täubel J J, Sharma V K, Chiu Y L, Lukasik N L, Pilmer B L, Pan W J
Charterhouse Clinical Research Unit, London, UK.
Aliment Pharmacol Ther. 2001 Nov;15(11):1807-17. doi: 10.1046/j.1365-2036.2001.01098.x.
To compare the 24-h intragastric pH effects of simplified lansoprazole suspension, 30 mg, administered nasogastrically, with pantoprazole, 40 mg, administered intravenously.
Thirty-six healthy adults were enrolled and given simplified lansoprazole suspension, 30 mg (nasogastrically), or pantoprazole, 40 mg (intravenously), once daily for five consecutive days in a cross-over fashion. Intragastric pH was monitored at baseline and on Days 1 and 5 of each treatment period. The pharmacokinetic parameters of lansoprazole and pantoprazole were also determined on Days 1 and 5.
No statistically significant changes in pharmacokinetic parameters occurred between Days 1 and 5 with either regimen, except for pantoprazole Cmax. On Days 1 and 5, significantly higher mean 24-h intragastric pH values were observed with 30 mg simplified lansoprazole suspension compared with 40 mg intravenous pantoprazole (Day 1, 3.13 vs. 2.67; Day 5, 3.95 vs. 3.61, respectively; P < 0.05). Additionally, 30 mg simplified lansoprazole suspension produced significantly (P < 0.05) higher percentages of time intragastric pH was above 3, 4, 5 or 6 as compared with 40 mg intravenous pantoprazole throughout Days 1 and 5.
A 30 mg dose of simplified lansoprazole suspension administered nasogastrically was consistently more effective at controlling intragastric pH than pantoprazole, 40 mg, administered intravenously.
比较经鼻胃管给予30毫克简化兰索拉唑混悬液与静脉注射40毫克泮托拉唑对24小时胃内pH值的影响。
招募36名健康成年人,采用交叉方式,连续5天每日给予一次30毫克简化兰索拉唑混悬液(经鼻胃管给药)或40毫克泮托拉唑(静脉注射)。在每个治疗期的基线、第1天和第5天监测胃内pH值。在第1天和第5天还测定了兰索拉唑和泮托拉唑的药代动力学参数。
除泮托拉唑的Cmax外,两种给药方案在第1天和第5天的药代动力学参数均无统计学显著变化。在第1天和第5天,与40毫克静脉注射泮托拉唑相比,30毫克简化兰索拉唑混悬液的24小时平均胃内pH值显著更高(第1天分别为3.13对2.67;第5天分别为3.95对3.61;P<0.05)。此外,在第1天和第5天,与40毫克静脉注射泮托拉唑相比,30毫克简化兰索拉唑混悬液使胃内pH值高于3、4、5或6的时间百分比显著更高(P<0.05)。
经鼻胃管给予30毫克简化兰索拉唑混悬液在控制胃内pH值方面始终比静脉注射40毫克泮托拉唑更有效。